Bryan Ball Sells 50,000 Shares of Whitehawk Therapeutics (NASDAQ:WHWK) Stock

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) insider Bryan Ball sold 50,000 shares of the company’s stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $3.57, for a total value of $178,500.00. Following the sale, the insider owned 522,551 shares in the company, valued at $1,865,507.07. The trade was a 8.73% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Bryan Ball also recently made the following trade(s):

• On Friday, April 10th, Bryan Ball sold 6,596 shares of Whitehawk Therapeutics stock. The stock was sold at an average price of $3.43, for a total value of $22,624.28.
• On Monday, March 2nd, Bryan Ball sold 1,834 shares of Whitehawk Therapeutics stock. The stock was sold at an average price of $3.31, for a total value of $6,070.54.

Whitehawk Therapeutics Stock Up 15.3%

Shares of NASDAQ WHWK opened at $4.00 on Wednesday. The business’s 50 day moving average price is $3.38 and its two-hundred day moving average price is $2.75. The company has a market cap of $188.80 million, a PE ratio of 8.51 and a beta of 0.57. Whitehawk Therapeutics, Inc. has a twelve month low of $1.39 and a twelve month high of $4.48.

Whitehawk Therapeutics (NASDAQ:WHWK) last announced its quarterly earnings results on Thursday, March 12th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.21.

Hedge Funds Weigh In On Whitehawk Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in WHWK. Vanguard Group Inc. acquired a new position in shares of Whitehawk Therapeutics in the third quarter valued at approximately $2,552,000. Peapod Lane Capital LLC acquired a new position in shares of Whitehawk Therapeutics in the third quarter valued at approximately $577,000. Dimensional Fund Advisors LP acquired a new position in shares of Whitehawk Therapeutics in the third quarter valued at approximately $84,000. Avoro Capital Advisors LLC acquired a new position in shares of Whitehawk Therapeutics in the third quarter valued at approximately $5,414,000. Finally, Suvretta Capital Management LLC acquired a new position in shares of Whitehawk Therapeutics in the third quarter valued at approximately $7,030,000. Institutional investors and hedge funds own 52.08% of the company’s stock.

Analyst Upgrades and Downgrades

WHWK has been the topic of a number of recent analyst reports. JonesTrading initiated coverage on Whitehawk Therapeutics in a research report on Monday, December 22nd. They set a “buy” rating and a $7.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Whitehawk Therapeutics in a research report on Friday, March 27th. Oppenheimer initiated coverage on Whitehawk Therapeutics in a research report on Thursday, February 5th. They set an “outperform” rating and a $6.00 price target on the stock. Finally, Wall Street Zen downgraded Whitehawk Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Whitehawk Therapeutics has a consensus rating of “Hold” and an average price target of $6.50.

About Whitehawk Therapeutics

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.